IL4 and primary cutaneous T-cell non-Hodgkin lymphoma: Bexarotene and extracorporeal photochemotherapy, two main therapies adopted in the management of CTCL, have for example the capacity to inhibit IL-4 production in the peripheral blood cells of SS patients [34,35].